On May 18, 2022 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, reported that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 (Press release, Citius Pharmaceuticals, MAY 18, 2022, https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-hc-wainwright-global-investment-conference-on-may-24-2022-301549451.html [SID1234614833]). Leonard Mazur, Chairman and CEO of Citius, will discuss the Company’s recent business developments and upcoming milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company’s investor relations team.